8.0788

1.47% -0.1712

Grifols Sa Adr (GRFS)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt GRFS? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$8.25

Offen:

$8.19

24-Stunden-Volumen:

164.78K

Relative Volume:

0.25

Marktkapitalisierung:

$5.51B

Einnahmen:

$8.62B

Nettoeinkommen (Verlust:

$573.80M

KGV:

11.43

EPS:

0.707

Netto-Cashflow:

$680.05M

1W Leistung:

+2.51%

1M Leistung:

+6.82%

6M Leistung:

-13.52%

1J Leistung:

-19.91%

1-Tages-Spanne:

$8.06

$8.20

1-Wochen-Bereich:

$7.68

$8.38

52-Wochen-Spanne:

$6.96

$10.23

Grifols Sa Adr Stock (GRFS) Company Profile

Firmenname

Grifols Sa Adr

Sektor

Healthcare (1084)

Branche

Drug Manufacturers - General (20)

Telefon

Adresse

Mitarbeiter

25,247

Twitter

Nächster Verdiensttermin

2026-08-24

Neueste SEC-Einreichungen

GRFS's Discussions on Twitter

Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GRFS Grifols Sa Adr	8.09	5.61B	8.62B	573.80M	680.05M	0.707
LLY Lilly Eli Co	1,265.04	1.14T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	270.49	658.89B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	264.88	470.00B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	151.37	375.50B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	157.38	304.70B	54.66B	13.58B	16.05B	7.0171

Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-12	Fortgesetzt	Morgan Stanley	Overweight
2024-03-12	Herabstufung	Deutsche Bank	Hold → Sell
2023-04-12	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-03-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-02-16	Hochstufung	Barclays	Underweight → Equal Weight
2023-01-18	Hochstufung	Jefferies	Hold → Buy
2022-04-08	Eingeleitet	Morgan Stanley	Equal-Weight
2021-11-05	Herabstufung	Deutsche Bank	Buy → Hold
2021-10-19	Herabstufung	Barclays	Overweight → Underweight
2021-10-06	Hochstufung	Citigroup	Neutral → Buy
2021-06-14	Hochstufung	Deutsche Bank	Hold → Buy
2021-04-20	Eingeleitet	Deutsche Bank	Hold
2021-03-23	Hochstufung	Credit Suisse	Neutral → Outperform
2021-03-11	Hochstufung	HSBC Securities	Hold → Buy
2020-10-01	Hochstufung	Citigroup	Sell → Neutral
2020-06-09	Herabstufung	Citigroup	Neutral → Sell
2020-06-09	Hochstufung	HSBC Securities	Reduce → Hold
2020-03-25	Herabstufung	Citigroup	Buy → Neutral
2019-06-27	Hochstufung	JP Morgan	Neutral → Overweight
2019-02-08	Herabstufung	Berenberg	Buy → Hold
2018-10-11	Hochstufung	Berenberg	Hold → Buy
2018-06-01	Eingeleitet	Barclays	Overweight
2017-10-31	Eingeleitet	Citigroup	Buy
2017-06-30	Herabstufung	Goldman	Buy → Neutral
2017-04-06	Eingeleitet	BofA/Merrill	Buy
2017-01-03	Hochstufung	JP Morgan	Neutral → Overweight
2016-02-09	Hochstufung	Berenberg	Hold → Buy
2016-01-04	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2015-12-02	Herabstufung	HSBC Securities	Buy → Hold
2015-11-20	Herabstufung	Berenberg	Buy → Hold
2015-04-28	Herabstufung	Berenberg	Buy → Hold

Alle ansehen

Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten

Aug 15, 2026

ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - tradingview.com

Aug 15, 2026

Aug 13, 2026

Grifols stock trades below $8 as investors weigh earnings outlook - Ad-hoc-news.de

Aug 13, 2026

Aug 10, 2026

Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK

Aug 10, 2026

Aug 02, 2026

Grifols ADRs Drop 4% to $7.87 as GRFS Nears Key Support at $7.48Insider Buying Alerts - Vinanet

Aug 02, 2026

Jul 29, 2026

Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 25, 2026

Jul 23, 2026

Grifols, S.A. (GRFS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Jul 23, 2026

Jul 22, 2026

[Latest] Global Botulinum Toxin in Urology Market Size/Share Worth USD 1.98 Billion by 2035 at a 6.08% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

Jul 22, 2026

Jul 16, 2026

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com - Investing.com UK

Jul 16, 2026

Jul 08, 2026

G0FB Forecast — Price Target — Prediction for 2027 - TradingView

Jul 08, 2026

Jul 04, 2026

GRFSGrifols SA ADR Options - Finviz

Jul 04, 2026

Jun 28, 2026

G0F Forecast — Price Target — Prediction for 2027 - TradingView

Jun 28, 2026

Grifols operations profile, Sunday focus on plasma and strategy - ad-hoc-news.de

Jun 28, 2026

Jun 26, 2026

A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Grifols, S.A. Class A Actuals & Estimates (BME:GRF) - TradingView

Jun 26, 2026

A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView

Jun 26, 2026

Jun 25, 2026

Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS

Jun 25, 2026

Jun 13, 2026

Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de

Jun 13, 2026

Jun 11, 2026